OncoMatch/Clinical Trials/NCT06022029
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Is NCT06022029 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including ONM-501 and Cemiplimab for triple negative breast cancer.
Treatment: ONM-501 · Cemiplimab — A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Urothelial Carcinoma
Melanoma
Cervical Cancer
Head and Neck Squamous Cell Carcinoma
Tumor Agnostic
Prior therapy
Must have received: antitumor therapy
progressing since last antitumor therapy, and for which no alternative standard therapy exists
Cannot have received: investigational therapy
Has received prior investigational therapy within 5 half-lives of the agent or 4 weeks before the first administration of study drug, whichever is shorter
Lab requirements
Blood counts
adequate bone marrow function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- California Research Institute · Los Angeles, California
- BRCR Global · Tamarac, Florida
- Gabrail Cancer Center Research · Canton, Ohio
- Ohio State University · Columbus, Ohio
- Allegheny Health Network · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify